Alphabet is plunging into the drug discovery business.
Over the last year, the tech behemoth and Google parent company has made a large and unlikely splash in the world of biology. DeepMind, its AI research outfit, wowed structural biologists last November by cracking the longstanding problem of predicting protein structure with its deep learning model, AlphaFold2. Eight months later, it amplified the impact of those discoveries by releasing both the model’s code and a database of more than 350,000 predicted protein structures to the public.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
